ClinicalTrials.gg
Not yet recruitingNCT07391566Updated Feb 6, 2026

LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation

A Phase 1/2 interventional study of LPM6690176 and Bevacizumab in Metastatic Colorectal Cancer (mCRC), sponsored by Luye Pharma Group Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-06.

Sponsored by Luye Pharma Group Ltd. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
99
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 231 studies testing bevacizumab in Colorectal Neoplasms — 50 open to participants now, 62 under way, 11 of them phase 3. Bevacizumab · Colorectal Neoplasms.

Planned enrollment
83rd of 225
99 · median 62
Started
2026
with 12 others
Phase 1/2
11 of 231
5 open now
Primary completion
2028-12
later than 51 of 61 live
Registered
220th of 231
by date

Among the 231 studies testing bevacizumab in Colorectal Neoplasms, this one is the 83rd largest by planned enrollment of the 225 interventional ones that give a count, is one of 13 that started in 2026, is one of 11 in phase 1/2, reaches primary completion later than 51 of the 61 other live ones, and was the 220th registered.

Colorectal Neoplasms

6,552 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

50 of the 231 studies testing bevacizumab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

45 more — sign in →

By country, each count listing its studies:

All 50 open studies →

About bevacizumab

Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 231 studies testing bevacizumab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This study is consist of phase 1b (dose escalation + safety run-in) and phase 2 (randomized, controlled). Phase 1b is planned to evaluate the safety and tolerability of LPM6690176 capsule in combination with chemotherapy and Bevacizumab in patients with RAS mutant metastatic colorectal cancer (mCRC), to observe the dose-limiting toxicity (DLT), and to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D); Phase 2 is planned to preliminarily evaluate the efficacy of LPM6690176 capsule in combination with chemotherapy + Bev vs. chemotherapy + Bev in patients with previously untreated, RAS mutant mCRC.

03

Conditions studied

  • Metastatic Colorectal Cancer (mCRC)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to provide a signed ;
  2. Age ≥ 18 years and ≤ 75 years, both male and female;
  3. confirmed colorectal cancer (CRC) with RAS mutation;
  4. Prior therapies for colorectal cancer:

(1 ) For phase 1b patients: who have failed or intolerable to prior therapy; (2) For phase 2 patients: who have not received prior systemic therapy for metastatic colorectal cancer.

5. At least one according to 1.1 criteria; 6. (ECOG) score of 0 or 1; 7. ≥ 6 months; 8. Adequate bone marrow and organ function; 9. Negative pregnancy test for women of . patients of childbearing potential should take effective measures during study drug treatment and until 6 months after initiation of product.

Exclusion criteria

Exclusion Criteria:

  1. Patients with known microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR) who are suitable for therapy as assessed by the investigator;
  2. Malignant tumors other than mCRC within 5 years before signing the ;
  3. Patients who did not recover from the AE of previous anti-tumor treatment to ≤ Grade 1;
  4. Patients with body cavity effusion requiring local treatment or poorly controlled effusion;
  5. Symptomatic , history of spinal cord compression or meningeal ;
  6. Underwent other therapeutic surgery other than diagnosis, , drainage, or expected to require major surgery during the study, or had unhealed wound, ulcer or fracture.
  7. Current or previous uncontrolled concomitant non-gastrointestinal disease including, but not limited to myocardial infarction, unstable angina, coronary artery/peripheral artery bypass grafting, heart failure, cerebrovascular accident, , pulmonary embolism, deep vein thrombosis, serious arrhythmia, current uncontrolled hypertension, previous history of hypertensive crisis or hypertensive brain disease, tumor invasion into major blood vessels, interstitial lung disease, interstitial pneumonia, pulmonary interstitial fibrosis, reversible posterior leukoencephalopathy syndrome (RPLS), etc.;
  8. Current or past presence of the gastrointestinal abnormalities, including but not limited to active peptic ulcer, gastrointestinal abnormalities prior to informed consent, active colitis, long-term anticoagulant therapy, antiplatelet therapy, etc.;
  9. Current or past significant risk of bleeding;
  10. Use of prohibited medication or therapy within the specified time;
  11. History of drug abuse or alcoholism;
  12. Known to any component of any product;
  13. Pregnant and lactating women;
  14. Other conditions that may increase the risk of the study or interfere with study results, in the judgment of the investigator.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
99 participants (estimated)

Study arms

  • Experimental
    LPM6690176 24 mg/m2

    LPM6690176 capsules administered 24 mg/m2 orally Day 1 through Day 5 and Day 15 through Day 19 of each 28-day cycle in combination with FOLFIRI+Bevacizumab

    Drug: LPM6690176 · Biological: Bevacizumab · Drug: FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)

  • Experimental
    LPM6690176 36 mg/m2

    LPM6690176 capsules administered 36 mg/m2 orally Day 1 through Day 5 and Day 15 through Day 19 of each 28-day cycle in combination with FOLFIRI+Bevacizumab

    Drug: LPM6690176 · Biological: Bevacizumab · Drug: FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)

  • Experimental
    LPM6690176 42 mg/m2

    LPM6690176 capsules administered 42 mg/m2 orally Day 1 through Day 5 and Day 15 through Day 19 of each 28-day cycle in combination with FOLFIRI+Bevacizumab

    Drug: LPM6690176 · Biological: Bevacizumab · Drug: FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)

Interventions

  • DrugLPM6690176

    LPM6690176 orally.

  • BiologicalBevacizumab

    Bevacizumab intravenously

  • DrugFOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)

    FOLFIRI intravenously

06

What researchers measure

Primary outcomes

  1. Phase Ib: Dose-limiting toxicities (DLTs)

    Time frame: From the first dose of study drug treatment through Cycle 1 (28 days)

  2. Phase Ib: Maximum tolerated dose (MTD)

    Time frame: From the first dose of study drug treatment through Cycle 1 (28 days)

  3. Phase 1b: Recommended Phase 2 Dose (RP2D)

    Time frame: From the first dose of study drug treatment through Cycle 1 (28 days)

  4. Phase 2: Overall response rate (ORR)

    Time frame: Approximately 2 years

Secondary outcomes

  1. Phase 1b: Overall response rate (ORR)

    Time frame: Approximately 2 years

  2. Duration of response (DOR)

    Time frame: Approximately 2 years

  3. Disease control rate (DCR)

    Time frame: Approximately 2 years

  4. Progression-free survival (PFS)

    Time frame: Approximately 2 years

  5. Overall survival (OS)

    Time frame: Approximately 2 years

  6. Maximum plasma concentration (Cmax)

    Time frame: From Pre-dose of Cycle 1 Day 1 and up to Cycle 1 Day 9 (Approximately 10 days, each cycle is 28 days)

  7. Time to maximum plasma concentration (Tmax)

    Time frame: From Pre-dose of Cycle 1 Day 1 and up to Cycle 1 Day 9 (Approximately 10 days, each cycle is 28 days)

  8. Area under the plasma concentration-time curve (AUC)

    Time frame: From Pre-dose of Cycle 1 Day 1 and up to Cycle 1 Day 9 (Approximately 10 days, each cycle is 28 days)

  9. Elimination half-life (t1/2)

    Time frame: From Pre-dose of Cycle 1 Day 1 and up to Cycle 1 Day 9 (Approximately 10 days, each cycle is 28 days)

  10. Trough observed plasma concentration (Ctrough)

    Time frame: From Pre-dose of Cycle 1 Day 1 and up to Cycle 1 Day 19 (Approximately 20 days, each cycle is 28 days)

  11. Adverse Events (AEs)

    Time frame: Approximately 2 years

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Dec 2028, 33 months later.

Of 158 industry-sponsored phase 1/2 interventional studies under Colorectal Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 82. This study's planned 33 months is below that.

Counting every sponsor, half of 260 studies reached it within 59 months; a quarter within 36 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2025
First posted
Feb 6, 2026
StartEst.
Mar 31, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Feb 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07391566
Responsible party
Sponsor
First posted
Feb 6, 2026
Start date
Mar 31, 2026 (estimated)
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Feb 6, 2026

Study contacts

Lin Shen, Doctor
Contact
doctorshenlin@sina.cn
0086-10-88196561

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bevacizumab

Start the discussion